Observational Study of Bloodstream Infections in Adults with Hematological Malignancies and Stem Cell Transplants Across the Middle East
Led by Hamad Medical Corporation · Updated on 2026-10-30
1000
Participants Needed
9
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a prospective observational study to understand bloodstream infections BSI in patients with hematological malignancies HM and recipients of hematopoietic stem cell transplants HSCT across the Middle East. The study aims to describe infection patterns, risk factors for inappropriate antimicrobial therapy, persistent infections, microbiological relapses, and overall mortality. This study is observational, with participants receiving standard care from their doctors.
The study enrolls adults aged 18 and older from multiple centers in Qatar, Saudi Arabia, Oman, the United Arab Emirates, and Jordan who have HM or have undergone HSCT and then develop a bloodstream infection. Data collected includes patient demographics, clinical details, infection sources, laboratory findings, antimicrobial treatments, and critical care needs. Follow-up occurs for 30 days after the initial blood culture, with data securely recorded and managed by the principal investigator.
Participants will have clinical and laboratory assessments during the 30-day follow-up, including microbiological evaluations. Researchers will measure the overall incidence of bloodstream infections per 1,000 patient days, persistent infections, microbiological relapse within 90 days, and mortality at 7, 14, and 30 days. The study uses statistical analysis to identify risk factors and outcomes, ensuring confidentiality and ethical oversight with a waiver of informed consent.
CONDITIONS
Brief Title
Middle East Study of Infections in Patients With Hematological Malignancies
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Have an active hematological malignancy or have received a hematopoietic stem cell transplant
Current bloodstream infection confirmed by a positive blood culture with at least one clinically significant microorganism being actively treated by a physician
You will not qualify if you...
Bloodstream infection occurring within 14 days of a previously enrolled bloodstream infection
Bloodstream infection occurring before resolution of active infection signs from a previously enrolled episode
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Observational Follow-up
Duration - 30 days
Participants receive their usual clinical care while study data on infection, treatments, and health status is collected for up to 30 days after the bloodstream infection diagnosis.
Regular clinical assessments as part of standard care
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Long-Term Follow-Up Study for Adults Previously Treated with Century Therapeutics Cellular Therapy
Phase I Study of Oral YY201 to Assess Safety and Early Effectiveness in Adults With Advanced Solid Tumors or Blood Cancers
Personalized Versus Standard Duration of Antibiotic Therapy in High-Risk Febrile Neutropenia Patients
Evaluating Clinical Stability-Driven Treatment and Outcomes in Bloodstream Infection
Bergonie Institut Profiling Study to Identify Molecular Alterations in Advanced Cancer Patients for Targeted Early Phase Treatments
Study of CXCR4-targeted 68Ga-pentixafor PETCT Compared to 18F-FDG PETCT for Diagnosing and Staging Hematological Malignancies
Exercise and Drug Effects on Immune Cells for Blood Cancer Cell Therapy
Early Phase 1 Study Testing Exercise and Beta Blockers in Healthy Donors
A Phase 1 Study to Evaluate Safety and Early Effects of OT-A201 Alone or With Other Treatments in Adults With Certain Blood Cancers or Solid Tumors
Evaluating G-CSF With or Without IL-11 for Blood Stem Cell Mobilization in Autologous Hematopoietic Stem Cell Transplantation
Testing Effects of Behavioral Coaching and Virtual Exercise on Aging in Blood Cancer Survivors Aged 50 and Older
Stem Cell Transplant Using Haploidentical Related Donor with Post-transplant Cyclophosphamide and Bortezomib
for Adults with Blood Cancers
After Fludarabine, Melphalan, and Total Body Irradiation Conditioning
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Dissecting bloodstream infections in febrile neutropenic patients with hematological malignancies, a decade-long single center retrospective observational study (2009-2019).
Halima El Omri, Regina Padmanabhan, Ruba Y Taha...
Prevalence and genetic characterization of clinically relevant extended-spectrum β-lactamase-producing Enterobacterales in the Gulf Cooperation Council countries.
Hamad A Hadi, Hissa Al-Hail, Leena Elsheikh Aboidris...
High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations.
Mariana Chumbita, Pedro Puerta-Alcalde, Lucrecia Yáñez...
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies.
Carlota Gudiol, Manuela Aguilar-Guisado, José Ramón Azanza...
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.
Diana Averbuch, Christina Orasch, Catherine Cordonnier...
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis.